|
parkinsons_disease
 9/9/2010 TPP Global Development Ltd Enters Into An Agreement With The University Of Edinburgh For Future Drug Development
TPP Global Development Ltd (TPP) announced an agreement with the University of Edinburgh to collaborate on the development of novel pre-clinical intellectual property originated within the University. TPP and the University of Edinburgh will focus on commercialisation opportunities in the areas of nervous system disorders, immunology/inflammation and oncology...
9/9/2010 Yeast Holds Clues To Parkinson's Disease
Yeast could be a powerful ally in the discovery of new therapeutic drugs to treat Parkinson's disease says a scientist presenting his work at the Society for General Microbiology's autumn meeting in Nottingham today...
9/9/2010 Roche And ReMYND Enter Into A Strategic Alliance To Develop First-In-Class Disease-Modifying Treatments For Parkinson's And Alzheimer's Disease
Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND announced that they have entered into an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson's and Alzheimer's patients by inhibiting α-synuclein and tau toxicity...
9/9/2010 Cognitive Impairment In People With Parkinson's Disease Exposed By Study
Queen's researchers have found that people with Parkinson's disease can perform automated tasks better than people without the disease, but have significant difficulty switching from easy to hard tasks. The findings are a step towards understanding the aspects of the illness that affect the brain's ability to function on a cognitive level...
9/9/2010 Santhera And Ipsen Enter Into Licensing Agreement For Fipamezole For The Treatment Of Dyskinesia In Parkinson's Disease
Santhera Pharmaceuticals (SIX: SANN) and Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) announced a license agreement for the development and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside of North America and Japan...
9/9/2010 New Light On The Mechanism Of Parkinson's Disease
A significant number of Parkinson's disease patients have a mutation of the enzyme Leucine-Rich Repeat Protein Kinase 2 (LRRK2, also known as dardarin). However, little is understood about how it is regulated or functions...
9/9/2010 New Parkinson's Gene Is Linked To Immune System
A hunt throughout the human genome for variants associated with common, late-onset Parkinson's disease has revealed a new genetic link that implicates the immune system and offers new targets for drug development...
9/9/2010 Impax Pharmaceuticals Completes Enrollment In ADVANCE-PD Phase III Trial Of IPX066 In Parkinson's Disease
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced that it has completed enrollment of its ADVANCE-PD trial. ADVANCE-PD is a multinational Phase III trial of its late-stage product IPX066 in advanced Parkinson's disease (PD) patients with motor fluctuations...
9/9/2010 Lipid Peroxides, More Sophisticated Than Their Reputation
Accumulation of lipid peroxides in the cell are associated with diseases and cellular stress. In the current issue of PNAS researchers at Helmholtz Zentrum München and the Swedish medical university Karolinska Institutet show that lipid peroxides also play an important, yet-unrecognized role in the regulation of receptor tyrosine kinases...
9/9/2010 Alnylam And Collaborators Publish New Pre-Clinical Research On Therapeutic Silencing Of Parkinson's Disease Gene
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS)...
9/9/2010 A Promising Target For Developing Treatments Against Parkinson's Disease
Researchers at Johns Hopkins have shown that using specific drugs can protect nerve cells in mice from the lethal effects of Parkinson's disease. The researchers' findings are published in the August 22 issue of Nature Medicine. The newly discovered drugs block a protein that, when altered in people, leads to Parkinson's disease...
9/9/2010 A Promising Target For Developing Treatments Against Parkinson's Disease
Researchers at Johns Hopkins have shown that using specific drugs can protect nerve cells in mice from the lethal effects of Parkinson's disease. The researchers' findings are published in the August 22 issue of Nature Medicine. The newly discovered drugs block a protein that, when altered in people, leads to Parkinson's disease...
9/9/2010 Brain Connections Break Down As We Age
It's unavoidable: breakdowns in brain connections slow down our physical response times as we age, a new study suggests...
9/9/2010 Human Induced Pluripotent Stem Cells Successfully Used To Treat Parkinson's In Rodents
Researchers at the Buck Institute for Age Research have successfully used human induced pluripotent stem cells (iPSCs) to treat rodents afflicted with Parkinson's Disease (PD)...
9/9/2010 Genetic Link Discovered Between Immune System, Parkinson's Disease
A team of researchers has discovered new evidence that Parkinson's disease may have an infectious or autoimmune origin. "Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease" appears online in Nature Genetics...
9/9/2010 Immune System Genes Linked To Parkinson's Disease
An international team of researchers conducting a genome-wide association study (GWAS) has discovered that common variants in immune system genes are linked to Parkinson's disease...
9/9/2010 Development Of Neurochip Technology Will Further Brain Research Of Alzheimer's, Parkinson's
The University of Calgary, Faculty of Medicine scientists who proved it is possible to cultivate a network of brain cells that reconnect on a silicon chip - or the brain on a microchip - have been involved in the development of new technology that monitors brain cell activity at a resolution never achieved before...
9/9/2010 TEMPO Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients
H. Lundbeck A/S (Lundbeck) and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension...
9/9/2010 Expectations May Affect Placebo Response In Patients With Parkinson's Disease
Individuals with Parkinson's disease were more likely to have a neurochemical response to a placebo medication if they were told they had higher odds of receiving an active drug, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals...
9/9/2010 TEMPO Extentension Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients
Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S have announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation...
9/9/2010 New Pathway To Parkinson's And Alzheimer's Diseases
Although their genetic underpinnings differ, Alzheimer's disease, Parkinson's disease and Huntington's disease are all characterized by the untimely death of brain cells...
9/9/2010 Study Identifies Molecular Mechanism Triggering Parkinson's Disease
Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady...
9/9/2010 REM Sleep Disorder Could Be Early Warning Of Parkinson's, Dementia That Develops Decades Later
American neurologists and sleep experts suggest in a recent study that rapid eye movement (REM) sleep behavior disorder could be an early sign of Parkinson's disease or dementia that develops up to 50 years later. You can read how neurologist and sleep specialist Dr Bradley F...
9/9/2010 Envoy To Seek New Parkinson's Disease Therapy With Scripps
Envoy Therapeutics Inc., a recently formed drug discovery company, announced that it has begun a research collaboration with The Scripps Research Institute to identify new drugs for Parkinson's disease (PD) that have greater efficacy and safety compared to current therapies...
9/9/2010 Helping Neurons Fix Themselves In Parkinson's Patients
A Michigan State University researcher is working to uncover how a protein known as parkin may help nerve cells fight off damage from Parkinson's disease, a strategy that could lead to new therapies for the degenerative ailment...
|
CanMedGlobal.com advantages
Save 50 to 90% off your local pharmacy
No Membership Fees
We Ship Internationally
Fast Service, Fast delivery time
|
|
|
|
|
